Mission Bio Announces High Precision Detection of Variants For Tapestri® Platform in NIST Genome Editing Consortium Initial Study

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium’s inaugural Interlab Study. This milestone collaboration underscores the exceptional precision and accuracy of Mission Bio’s Tapestri platform and supports…
Click here to view original post